GlassScriptPhysician profile
Nishtha Garg
NPI 1013505189
$3,636.50
in general payments reported to CMS, 2019-2025
24 companies · $568 in 2025
The $568 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $785 · 2022: $542 · 2023: $441 · 2024: $1,300 · 2025: $568.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,309.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,309.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $704.20 | 2021-2024 | Ozempic, Rybelsus, Wegovy |
| Janssen Pharmaceuticals, INC | $581.04 | 2021-2024 | Spravato |
| Amgen INC. | $439.89 | 2022-2025 | Evenity, Otezla, Repatha |
| Neurocrine Biosciences, INC. | $256.06 | 2024-2025 | Ingrezza |
| Janssen Scientific Affairs, LLC | $127.42 | 2025 | Tremfya |
| Ibsa Pharma INC. | $125.00 | 2024 | Tirosint |
| Pharming Healthcare, INC. | $124.99 | 2024 | Ruconest |
| Abbott Laboratories | $124.85 | 2023 | Freestyle Libre 3 |
| Abbvie INC. | $116.49 | 2021-2025 | |
| Astellas Pharma US INC | $114.30 | 2025 | Veozah |
| Abiomed | $106.72 | 2025 | |
| Sanofi-Aventis U.S. LLC | $102.64 | 2023 | |
| Viiv Healthcare Company | $96.60 | 2024 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $96.16 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $90.74 | 2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $90.66 | 2023-2024 | Airsupra, Farxiga |
| Genzyme Corporation | $67.08 | 2022 | |
| Glaxosmithkline, LLC. | $66.41 | 2023-2024 | Shingrix |
| Lilly USA, LLC | $60.46 | 2022-2024 | Jardiance, Mounjaro |
| Merck Sharp & Dohme LLC | $54.82 | 2022 | |
| Ethicon US, LLC | $27.07 | 2022 | |
| Dexcom, INC. | $25.12 | 2021-2022 | |
| Alexion Pharmaceuticals, INC. | $20.83 | 2022 | |
| Pfizer INC. | $16.95 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nishtha Garg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.